| [1] |
刘杨从, 李妍, 张耕. 临床药师参与1例过敏体质患者放射碘的治疗实践[J]. 中国医院用药评价与分析, 2016, 16(1): 131-133. https://www.cnki.com.cn/Article/CJFDTOTAL-YYPF201601047.htm
|
| [2] |
CHOI Y H, CHOI W Y, KANG H-C, et al. Drug rash induced by levothyroxine tablets[J]. Thyroid, 2012, 22(10): 1090. doi: 10.1089/thy.2011.0462
|
| [3] |
BAYLESS T M, BROWN E, PAIGE D M. Lactase non-persistence and lactose intolerance[J]. Curr Gastroenterol Rep, 2017, 19(5): 23. doi: 10.1007/s11894-017-0558-9
|
| [4] |
SANTAGUIDA M G, VIRILI C, DEL DUCA S C, et al. Thyroxine softgel capsule in patients with gastric-related T4 malabsorption[J]. Endocrine, 2015, 49(1): 51-57. doi: 10.1007/s12020-014-0476-7
|
| [5] |
王坤玲, 何向辉, 张桂芝, 等. 家族性异常白蛋白血症性高甲状腺素血症合并甲状腺癌一例报道及文献复习[J]. 中华内分泌代谢杂志, 2018, 34(7): 602-604. doi: 10.3760/cma.j.issn.1000-6699.2018.07.014
|
| [6] |
张维, 崔海滨, 葛怀娥. 纳米碳负显影甲状旁腺在甲状腺癌手术中应用价值[J]. 现代仪器与医疗, 2016, 22(2): 50-51, 59. https://www.cnki.com.cn/Article/CJFDTOTAL-XDYI201602018.htm
|
| [7] |
MORRIS J C. How do you approach the problem of TSH elevation in a patient on high-dose thyroid hormone replacement?[J]. Clin Endocrinol(Oxf), 2009, 70(5): 671-673. doi: 10.1111/j.1365-2265.2009.03536.x
|
| [8] |
MCNALLY L J, OFIAELI C I, OYIBO S O. Treatment-refractory hypothyroidism[J]. BMJ, 2019, 364: l579.
|
| [9] |
BACH-HUYNH T G, NAYAK B, LOH J, et al. Timing of levothyroxine administration affects serum thyrotropin concentration[J]. J Clin Endocrinol Metab, 2009, 94(10): 3905-3912. doi: 10.1210/jc.2009-0860
|
| [10] |
CENTANNI M. Thyroxine treatment: absorption, malabsorption, and novel therapeutic approaches[J]. Endocrine, 2013, 43(1): 8-9. doi: 10.1007/s12020-012-9814-9
|
| [11] |
DE GROOT J W B, ZONNENBERG B A, PLUKKER J T M, et al. Imatinib induces hypothyroidism in patients receiving levothyroxine[J]. Clin Pharmacol Ther, 2005, 78(4): 433-438. doi: 10.1016/j.clpt.2005.06.010
|
| [12] |
SHERMAN S I, WIRTH L J, DROZ J P, et al. Motesanib diphosphate in progressive differentiated thyroid cancer[J]. N Engl J Med, 2008, 359(1): 31-42. doi: 10.1056/NEJMoa075853
|
| [13] |
ROBINSON S I, HOBDAY T J, SATHANANTHAN A, et al. Can sorafenib cause hypothyroidism?[J]. J Chemother, 2007, 19(3): 352-353. doi: 10.1179/joc.2007.19.3.352
|
| [14] |
JUNGLEE N A, SCANLON M F, REES D A. Increasing thyroxine requirements in primary hypothyroidism: don't forget the urinalysis![J]. J Postgrad Med, 2006, 52(3): 201-203. http://europepmc.org/abstract/MED/16855322
|
| [15] |
SINGH N, WEISLER S L, HERSHMAN J M. The acute effect of calcium carbonate on the intestinal absorption of levothyroxine[J]. Thyroid, 2001, 11(10): 967-971. doi: 10.1089/105072501753211046
|
| [16] |
HAUGEN B R, ALEXANDER E K, BIBLE K C, et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer[J]. Thyroid, 2016, 26(1): 1-133. doi: 10.1089/thy.2015.0020
|
| [17] |
VIRILI C, TRIMBOLI P, ROMANELLI F, et al. Liquid and softgel levothyroxine use in clinical practice: state of the art[J]. Endocrine, 2016, 54(1): 3-14. doi: 10.1007/s12020-016-1035-1
|
| [18] |
ERNST F R, SANDULLI W, ELMOR R, et al. Retrospective study of patients switched from tablet formulations to a gel cap formulation of levothyroxine: results of the CONTROL switch study[J]. Drugs R D, 2017, 17(1): 103-115. doi: 10.1007/s40268-016-0150-z
|
| [19] |
FALLAHI P, FERRARI S M, ANTONELLI A. Oral L-thyroxine liquid versus tablet in patients with hypothyroidism without malabsorption: a prospective study[J]. Endocrine, 2016, 52(3): 597-601. doi: 10.1007/s12020-015-0836-y
|
Figures(2) / Tables(3)
Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com
Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2
Supported by:
Beijing Renhe Information Technology Co., Ltd.
DownLoad:
